- Altasciences has appointed Marie-Hélène Raigneau as Chief Executive Officer and named Chris Perkin to its Board of Directors, effective February 24, 2026.
- The leadership transition follows a 12-month succession plan, with Perkin stepping down after 50 years in drug development.
Altasciences has appointed Marie-Hélène Raigneau as Chief Executive Officer and named Chris Perkin to its Board of Directors, both effective February 24, 2026. The announcement follows a leadership transition that has been underway for the past 12 months.
Perkin, who joined Altasciences as CEO in 2010, will step aside after 50 years in drug development. During his tenure, the company expanded from a clinical research organization focused on generic drug testing into a fully integrated early-phase contract research and contract drug manufacturing organization operating across nine North American locations. In 2025, Altasciences’ integrated model supported 11 of the 46 FDA approvals for novel drugs, representing 24% of all approvals.
Raigneau has been with Altasciences since 2012 and most recently served as President. Over the past 14 years, she has held senior roles spanning business development, research services, operations, and executive leadership. She has contributed to the expansion of the company’s CRO services, including project management, medical writing, biostatistics, and programming, and has overseen investments in bioanalytical laboratory expansion in Canada and the United States.
“Marie-Hélène has been a key member of our executive leadership team, partnering with me on company strategy, operational priorities, and long-term growth,” said Chris Perkin. “Her deep understanding of our business, the drug development pipeline, our people, and our clients, combined with her strong leadership and values-driven approach, position her exceptionally well to lead Altasciences into its next chapter.”
Altasciences operates as a mid-sized, fully integrated early-phase contract research and contract manufacturing organization primarily in Canada and the U.S., and is owned by Novo Holdings. The existing executive leadership team, including the Co-Chief Operating Officers and other senior executives, will continue in their roles.
